Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
CENTOCOR, INC.
🇺🇸
United States
Country
🇺🇸
United States
Ownership
Subsidiary
Employees
1.2K
Market Cap
-
Website
http://www.centocor.com
Clinical Trials
Related News
A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type Psoriasis
Phase 3
Completed
Conditions
Psoriasis
Interventions
Drug: Placebo - Controlled Period (CP)
Drug: Ustekinumab 45 mg - CP
Drug: Placebo to ustekinumab 45 mg - after CP
Drug: Ustekinumab 45 mg - after CP
Subscribe
First Posted Date
2008-09-05
Last Posted Date
2013-03-29
Lead Sponsor
Centocor, Inc.
Target Recruit Count
121
Registration Number
NCT00747344
Subscribe
A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Phase 2
Completed
Conditions
Arthritis, Rheumatoid
Interventions
Drug: CNTO 136 100 mg
Drug: CNTO 136 50 mg
Drug: CNTO 136 25 mg
Drug: Placebo
Drug: Methotrexate
Subscribe
First Posted Date
2008-07-21
Last Posted Date
2018-01-23
Lead Sponsor
Centocor, Inc.
Target Recruit Count
187
Registration Number
NCT00718718
Subscribe
A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma
Phase 2
Withdrawn
Conditions
Asthma
Interventions
Biological: CNTO 148 / Golimumab
Biological: placebo
Subscribe
First Posted Date
2008-05-12
Last Posted Date
2015-04-10
Lead Sponsor
Centocor, Inc.
Registration Number
NCT00675649
Subscribe
A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector
Early Phase 1
Completed
Conditions
Psoriasis
Rheumatoid Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Interventions
Device: Pre-filled Auto-injector Containing Placebo
Subscribe
First Posted Date
2008-03-26
Last Posted Date
2015-04-10
Lead Sponsor
Centocor, Inc.
Target Recruit Count
68
Registration Number
NCT00643526
Subscribe
An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer
Phase 2
Completed
Conditions
Prostatic Neoplasms
Interventions
Drug: Docetaxel
Drug: Prednisone
Drug: Placebo
Biological: Intetumumab
Subscribe
First Posted Date
2007-10-01
Last Posted Date
2013-06-20
Lead Sponsor
Centocor, Inc.
Target Recruit Count
131
Registration Number
NCT00537381
Subscribe
First Study of the Safety of CNTO 888 in Patients With Solid Tumors
Phase 1
Completed
Conditions
Cancer
Subscribe
First Posted Date
2007-10-01
Last Posted Date
2010-10-22
Lead Sponsor
Centocor, Inc.
Target Recruit Count
44
Registration Number
NCT00537368
Subscribe
A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa
Phase 1
Terminated
Conditions
Retinitis Pigmentosa
Interventions
Drug: CNTO 2476
Subscribe
First Posted Date
2007-04-11
Last Posted Date
2014-06-26
Lead Sponsor
Centocor, Inc.
Target Recruit Count
7
Registration Number
NCT00458575
Subscribe
An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque Psoriasis
Phase 3
Completed
Conditions
Psoriasis
Interventions
Drug: CNTO 1275 45 mg
Drug: CNTO 1275 90 mg
Drug: Etanercept 50 mg
Subscribe
First Posted Date
2007-03-30
Last Posted Date
2012-11-21
Lead Sponsor
Centocor, Inc.
Target Recruit Count
903
Registration Number
NCT00454584
Subscribe
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
Phase 1
Completed
Conditions
Lymphoma, Non-Hodgkin
Multiple Myeloma
Giant Lymph Node Hyperplasia
Interventions
Drug: CNTO 328
Subscribe
First Posted Date
2006-12-18
Last Posted Date
2014-07-01
Lead Sponsor
Centocor, Inc.
Target Recruit Count
67
Registration Number
NCT00412321
Subscribe
An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple Myeloma
Phase 2
Completed
Conditions
Multiple Myeloma
Interventions
Biological: Siltuximab
Drug: Dexamethasone
Subscribe
First Posted Date
2006-11-22
Last Posted Date
2014-05-14
Lead Sponsor
Centocor, Inc.
Target Recruit Count
53
Registration Number
NCT00402181
Subscribe
Prev
1
2
3
4
5
8
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy